Repeatability of the timed 25-foot walk test for individuals with multiple sclerosis

Abstract

Objective:

The purpose of this study was to determine if there is a practice effect present in the timed 25-foot walk in ambulatory individuals with multiple sclerosis.

Design:

Thirty six people (30 women and 6 men) diagnosed with relapsing remitting multiple sclerosis participated in two testing sessions, one week apart. Each participant performed two sequential trials of the timed 25-foot walk test per session and the walk performance was measured with a laser timing system.

Results:

We observed improvements in walking speed between the two trials of session one (trial one: 6.42 (0.09) vs. trail two: 5.97 (0.08) seconds, p < 0.001). Within session two, performance remained stable (trial three: 5.71 (0.07) vs. trial four: 5.63 (0.07) seconds, p > 0.05). We also observed a significant improvement in walking speed when averages of the two trials were compared across sessions (session 1: 6.19 (0.09) vs. session 2: 5.67 (0.07) seconds, p < 0.01).

Conclusions:

Based on our results, familiarization of the timed 25-foot walk test improves stability of walk performance scores in ambulatory individuals with relapsing remitting multiple sclerosis.

Keywords

Multiple sclerosis assessment clinical tests mobility repeatability

Get full access to this article

View all access options for this article.

References

Kurtzke

. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444–1452.

Noseworthy

. Clinical scoring methods for multiple sclerosis. Ann Neurol 1994; 36 Suppl: S80–85.

Hobart

Freeman

Thompson

. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000; 123(Pt 5): 1027–1040.

Sharrack

Hughes

Soudain

Dunn

. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999; 122(Pt 1): 141–159.

Whitaker

McFarland

Rudge

Reingold

. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1995; 1(1): 37–47.

Kaufman

Moyer

Norton

. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler 2000; 6(4): 286–290.

Rudick

Antel

Confavreux

. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42(3): 379–382.

Rudick

Antel

Confavreux

. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996; 40(3): 469–479.

Fischer

Rudick

Cutter

Reingold

. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999; 5(4): 244–250.

10.

Cutter

Baier

Rudick

. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122(Pt 5): 871–882.

11.

Cohen

Cutter

Fischer

. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001; 58(6): 961–967.

12.

Soilu-Hanninen

Aivo

Lindstrom

. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83(5): 565–571.

13.

Spain

St George

Salarian

. Body-worn motion sensors detect balance and gait deficits in people with multiple sclerosis who have normal walking speed. Gait Posture 2012; 35(4): 573–578.

14.

Gijbels

Dalgas

Romberg

. Which walking capacity tests to use in multiple sclerosis? A multicentre study providing the basis for a core set. Mult Scler 2012; 18(3): 364–371.

15.

Broekmans

Roelants

Feys

. Effects of long-term resistance training and simultaneous electro-stimulation on muscle strength and functional mobility in multiple sclerosis. Mult Scler 2011; 17(4): 468–477.

16.

Bosma

Kragt

Knol

Polman

Uitdehaag

. Clinical scales in progressive MS: predicting long-term disability. Mult Scler 2012; 18(3): 345–350.

17.

Phan-Ba

Pace

Calay

. Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis. Neurorehabil Neural Repair 2011; 25(7): 672–679.

18.

Ratchford

Shore

Hammond

. A pilot study of functional electrical stimulation cycling in progressive multiple sclerosis. Neuro Rehabilitation 2010; 27(2): 121–128.

19.

Widener

Allen

Gibson-Horn

. Balance-based torso-weighting may enhance balance in persons with multiple sclerosis: preliminary evidence. Arch Phys Med Rehabil 2009; 90(4): 602–609.

20.

Sutliff

Naft

Stough

Lee

Arrigain

Bethoux

. Efficacy and safety of a hip flexion assist orthosis in ambulatory multiple sclerosis patients. Arch Phys Med Rehabil 2008; 89(8): 1611–1617.

21.

Ytterberg

Johansson

Andersson

Widen Holmqvist

von Koch

. Variations in functioning and disability in multiple sclerosis. A two-year prospective study. J Neurol 2008; 255(7): 967–973.

22.

Solari

Radice

Manneschi

Motti

Montanari

. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 2005; 228(1): 71–74.

23.

Schwid

Goodman

McDermott

Bever

Cook

. Quantitative functional measures in MS: what is a reliable change? Neurology 2002; 58(8): 1294–1296.

24.

Rudick

Cutter

Reingold

. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials. Mult Scler 2002; 8(5): 359–365.

25.

Rosti-Otajarvi

Hamalainen

Koivisto

Hokkanen

. The reliability of the MSFC and its components. Acta Neurol Scand 2008; 117(6): 421–427.